In The News: Henry Ford Health System and G3 Pharmaceuticals to Develop and Commercialize Treatment for Diastolic Heart Failure

November 01, 2018

G3 Pharmaceuticals, a development-stage biopharmaceutical company located in Burlington, MA, and Henry Ford Health System, have announced the signing of an exclusive license and option agreement for the development and commercialization of galectin-3 inhibitors for treatment of diastolic heart failure, also known as heart failure with preserved ejection fraction or HFpEF.

Read the full article here:

https://www.prnewswire.com/news-releases/g3-pharmaceuticals-signs-exclusive-license-and-option-agreement-for-treating-diastolic-heart-failure-hfpef-by-inhibiting-galectin-3-300739964.html